Zydus’ Third Quarter Results Met With Mixed Analyst Reactions
As Firm Strikes Fresh Deal With Synthon For 505(b)(2) Product
Zydus’ latest results faced scrutiny from industry analysts due to a mixed performance where weaker revenue in the Indian company’s domestic market was offset by growth in the US. Meanwhile, the firm has just agreed a deal with Synthon for a 505(b)(2) hybrid product in the US.
